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Abstract
Changes in miRNA expression are a common feature in colon cancer. Those changes occurring in the transition from normal
to adenoma and from adenoma to carcinoma, however, have not been well defined. Additionally, miRNA changes among
tumor subgroups of colon cancer have also not been adequately evaluated. In this study, we examined the global miRNA
expression in 315 samples that included 52 normal colonic mucosa, 41 tubulovillous adenomas, 158 adenocarcinomas with
proficient DNA mismatch repair (pMMR) selected for stage and age of onset, and 64 adenocarcinomas with defective DNA
mismatch repair (dMMR) selected for sporadic (n=53) and inherited colon cancer (n=11). Sporadic dMMR tumors all had
MLH1 inactivation due to promoter hypermethylation. Unsupervised PCA and cluster analysis demonstrated that normal
colon tissue, adenomas, pMMR carcinomas and dMMR carcinomas were all clearly discernable. The majority of miRNAs that
were differentially expressed between normal and polyp were also differentially expressed with a similar magnitude in the
comparison of normal to both the pMMR and dMMR tumor groups, suggesting a stepwise progression for transformation
from normal colon to carcinoma. Among the miRNAs demonstrating the largest fold up- or down-regulated changes ($4),
four novel (miR-31, miR-1, miR-9 and miR-99a) and two previously reported (miR-137 and miR-135b) miRNAs were identified
in the normal/adenoma comparison. All but one of these (miR-99a) demonstrated similar expression differences in the two
normal/carcinoma comparisons, suggesting that these early tumor changes are important in both the pMMR- and dMMR-
derived cancers. The comparison between pMMR and dMMR tumors identified four miRNAs (miR-31, miR-552, miR-592 and
miR-224) with statistically significant expression differences ($2-fold change).
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Introduction
Colon cancer (CC) is one of the leading causes of cancer deaths
worldwide, with approximately 148,000 new cases reported in the
United States in 2009 [1]. The progression to CC is considered a
stepwise process with the accumulation of different genetic and
epigenetic alterations leading to a transformation from a normal
cell to a premalignant tumor and finally to a malignant and
potentially metastatic tumor (normal to adenoma to carcinoma
sequence). Current data clearly demonstrate the presence of
heterogeneity in this sequence of events. These include: (i) the
development of different types of precancerous lesions such as
villous adenoma, tubular adenoma, tubulovillous adenoma, and
serrated polyp with presumed differences in molecular defects; (ii)
transition to invasive cancer demonstrating very different molec-
ular abnormalities (e.g., tumors with and without defective DNA
mismatch repair); and finally, (iii) the development of sporadic
versus various forms of hereditary CC. The underlying factors
responsible for this heterogeneity, however, are still largely
unknown.
One of the clearest distinctions demonstrated so far for
sporadic CC is based on the presence or absence of functional
DNA mismatch repair (MMR) [2,3,4]. Tumors with defective
MMR (dMMR) have been identified in ,20% of sporadic CC
and are characterized by the presence of a particular tumor
phenotype, termed microsatellite instability (MSI). In sporadic
CC, three distinct MSI phenotypes have been described: MSS,
MSI-L and MSI-H [5]. The MSI-H phenotype is associated
with distinct clinicopathologic features [2,3,4], including a
more favorable outcome [6]. Among sporadic CC, the majority
o fM S I - Hc a s e sr e s u l t sf r o mi n a c t i v a t i o no fMLH1 due to
promoter hypermethylation (,95%) [2,3,4]. The remaining
,80% of CC with proficient MMR (pMMR), on the other
hand, follow a chromosomal instability (CIN) pathway and
are associated with a high frequency of aneuploidy and allelic
imbalance [7].
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age at diagnosis in the mid-60 s, roughly 15–20% of cases arise within
familial aggregates, with known genetic conditions accounting only for
a small fraction of these. While hereditary CC has been recognized for
some time, the identity of genes involved in the disease process has only
recently been identified for many of the hereditary conditions. The
most prevalent hereditary form of CC is Hereditary Non-Polyposis
Colon Cancer (HNPCC), accounting for ,2–3% of all cases [8].
For HNPCC, germline mutations in the DNA MMR genes are
also responsible for this condition, with MLH1 and MSH2
accounting for the majority of cases (,40% each) and MSH6
and PMS2 accounting for a smaller percentage, ,10% and 5%,
respectively [2,8]. Tumors from these patients are also character-
ized by the presence of MSI-H and by loss of MMR protein
expression for the affected gene. Thus, the molecular etiology of
tumors involving dMMR is very heterogeneous, involving several
different genes and numerous mechanisms of gene inactivation,
including epigenetic, somatic and germline alterations.
There appears to be at least two significant pathways leading to
sporadic and hereditary CC. The first pathway, involving dMMR,
is thought to originate in a serrated precursor (the sessile serrated
adenoma) and accounts for all sporadic MSI-H CC (although not
all cancers arising via the serrated pathway are MSI-H). HNPCC
also gives rise to MSI-H CC. The second pathway is thought to
arise from tubulo/villous adenomas and leads to sporadic CC or
FAP-related CC characterized by tumor CIN and pMMR. Our
understanding of these pathways at a molecular level and their
involvement in the transition from normal to polyp to carcinoma,
although improving, remains incomplete.
Genome-wide approaches (expression profiling, genome-wide
SNPanalysis, aCGH,nextgenerationsequencing)arecontinuingto
refine our understanding of the process of tumorigenesis. The
discovery of a growing class of small non-coding RNAs, including
miRNAs, has revealed an even greater level of complexity for
cancer biology [9,10,11]. microRNAs (miRNAs) are 18–24 nt small
non-coding RNA molecules that predominantly inhibit gene
expression at the post-transcriptional level [9]. As miRNAs regulate
the expression of a large number of protein-encoding genes, a wide
range of biological processes are affected, such as metabolism,
organogenesis, development, and the determination of cell fate,
including death [10]. Altered expression of miRNAs has also been
associated with a variety of human disease, including cancer [11].
Although a growing number of studies have addressed miRNA
expression in CC [12,13,14,15,16,17,18,19,20], few have been
published on premalignant lesions in the colon [21,22,23,24,25]. In
particular, the role of miRNAs in the transition between normal
colon and polyp and between polyp and cancer is not understood.
In this study, global miRNA (735 miRNA targets) expression was
evaluated in 315 samples (52 normal colonic mucosa and 263 colon
tumors) using the BeadArray
TM platform (Illumina, Inc.) [26].
Samples selected for analysis were categorized by a number of
clinical and molecular criteria to explore tumor heterogeneity in
more detail, to discover biologically relevant miRNAs and to address
transitional changes from normal to adenoma and adenoma to
carcinoma. Tumor types included tubulovillous adenomas, adeno-
carcinomas with dMMR selected for both sporadic and inherited
cases, and adenocarcinomas with pMMR selected for stage (A, B, C,
and D) and age of onset (old- versus young-onset disease).
Methods
Ethics Statement
The Mayo Clinic Institutional Review Board reviewed and
approved for human studies the protocol entitled ‘‘The
Identification and Validation of miRNA Signature Profiles as
Biomarkers for Colon Cancer Progression’’ from Dr. Stephen
N. Thibodeau. The Committee noted that the human studies
aspects involve the use of samples collected under IRB-approved
protocols. The Committee determined that the consenting
process allows for future use of the samples as exemplified in
the current protocol. The majority of patients provided written
informed consent. For those who did not, samples were
anonymized.
Sample Selection
Specimens from patients with CC or polyps were selected from
two separate tumor registries. The first collection of samples was
obtained from all patients that underwent surgical resection for
CC during a three-year period from 1995 to 1998 (unselected).
The second collection, initiated in 2000, is an ongoing collection of
biospecimens from Mayo Clinic Rochester patients with colorectal
neoplasia. For the later registry, no pre-selection criteria have been
used by the registry except that only those polyps with a diameter
of $7 mm are collected for future use.
All tissue samples were snap frozen in liquid nitrogen at the time
of collection and then stored at 280uC for later use. Normal areas
of colonic epithelium were obtained from either the margin of
resection or adjacent to the tumor. All but one of the normal tissue
samples used for this study were matched with tumors. Rectal
cancers were excluded. Polyps were evaluated for histologic type,
with only tubulovillous adenomas selected for study. Pathologic
tumor staging was classified according to Dukes’ criteria [27].
Patient chart reviews were performed to obtain clinical charac-
teristics of the tumor, including tumor site, stage and age at
diagnosis.
Tumor Processing and RNA Extraction
Frozen tissue was cut on a cryostat to generate hematoxylin and
eosin (H&E) stained slides. For polyps, areas with at least 50%
adenoma were macro-dissected. For cancers, areas containing at
least 70% neoplastic cells or greater were macro-dissected. Tissue
sizes equivalent to 7 mm
2 and 10-microns thick were sectioned
and placed in a vial containing 400 uL of RLT buffer (QIAGEN,
Chatsworth, CA) including 4 mLo fb-mercaptoethanol. The vial
was then stored at 280uC until utilized for RNA extraction using
TRIzolH LSTrizol (Invitrogen, Corp., Carlsbad, CA) according
to the manufacturer’s instructions.
DNA MMR Status
The majority of tumors with defective DNA mismatch repair
selected for this study were the same as those previously reported
upon and have been extensively characterized [28]. Tumor MSI
was assessed by comparing paired tumor and normal mucosa
DNA isolated (Qiagen DNA extraction kit) from formalin-fixed,
paraffin-embedded (FFPE) material with the use of 3–18
microsatellite markers, as previously described [28]. Tumors were
classified as MSI-H if $30% of markers demonstrated instability,
MSI-L if ,30% demonstrated instability, and MSS if none of the
markers demonstrated instability.
Immunohistochemical (IHC) analysis for protein expression was
performed on FFPE samples for MLH1 and MSH2 (all cases) and
MSH6 and PMS2 (subset), as previously described [29]. DNA
dMMR was defined by the presence of MSI (MSI-H) and/or the
absence of protein expression for MLH1, MSH2, MSH6 or
PMS2. DNA pMMR was defined by the absence of high levels of
microsatellite instability (MSS/MSI-L) and by the presence of
normal protein expression for MLH1, MSH2, MSH6 and PMS2.
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further tested to determine the cause of gene inactivation, i.e.,
epigenetic (sporadic) versus germline (inherited). Either a methyl-
ation-specific PCR-based assay or a HPAII enzyme digest based
assay was utilized to test for promoter hypermethylation [30]. In
addition, a PCR-based assay for alterations within the V600E
mutation in BRAF was also performed. MLH1 cases demonstrat-
ing MLH1 promoter hypermethylation were classified as sporadic
(dMMR1). MLH1 cases with wild type BRAF and without MLH1
promoter hypermethylation were classified as germline (dMMR2).
Cases involving MSH2, MSH6 or PMS2 (by loss of protein
expression by IHC or by germline testing) were also classified as
germline (dMMR2).
miRNA Profiling
Global miRNA (735 miRNA targets) expression was evaluated
using the BeadArray
TM platform (Illumina, Inc.) essentially as
described by Sarver et al. [16]. For each sample tested, 200 ng of
total RNA was utilized for the analysis.
Statistical Analysis
Study Design. Separate randomization schemes were created
to determine the order of tissue cryosectioning, RNA extraction
and the allocation of samples to the 96-well Sentrix Array Matrix
(SAM) plates to ensure that sample groups of interest and
demographic characteristics were well balanced over several
potential experimental effects.
Quality assessments. A total of 336 tissue samples (281
tumors and 55 normal tissue samples) from 282 subjects were
initially tested with the Illumina platform. For 54 of the patients,
both normal and tumor tissue were obtained from the same
individual (Table 1). For quality-control purposes, 8 samples
were tested one additional time and 5 samples were tested three
additional times (test for reproducibility), resulting in a total
of 23 replicate samples tested (total tested =359). Twenty-five
additional negative and cutting controls were also utilized to assess
overall quality.
In addition to the laboratory quality-control assessments, global
quality and bias were assessed via several plotting techniques. All
analyses were performed on the log2 scale and results are
presented on the fold-change scale. Box-and-whisker plots were
used to assess global mean shifts in miRNA distribution or
concentration between specimens and SAMs. Pair-wise minus
versus average (MVA) plots for two specimens, defined as the per-
probe difference between the two specimens (vertical axis) versus
the per-probe average (horizontal axis) for the two specimens [31],
were used to assess agreement between technical replicates.
Residual MVA plots for a given specimen, defined as the
difference between that specimen and the average of all specimens
(vertical axis) versus the average of all specimens (horizontal axis)
[32], were used to assess the existence of and functional form of,
e.g., (non)linearity biases as a function of abundance. Plots of
principal component analysis (PCA) results were used to examine
(dis)similarity of specimens to negative control specimens and
existence of SAM effects. Box plots and dot plots were used to
assess the nature and consistency of per-probe SAM effects.
Detection rates were assessed for each specimen, with probe
detection defined as p-values ,0.01.
Based on these quality assessment analyses, a total of 21 of the
359 samples (including some replicates) were removed from
further study. Twelve were found to be more similar in expression
distribution to negative control specimens based on box plots,
detection rates and PCA plots and one specimen had an extremely
high but narrow range of expression. An additional seven
specimens had obviously different floor and ceiling effects in
residual MVA plots and clustered closer to the negative control
specimens in PCA. One additional sample was eliminated since it
was the only one in its class. Thus, there were 338 samples (318
unique and 20 replicates) from 268 subjects remaining for analysis.
Preprocessing. The abundance distribution of the 735
miRNA and 20 control probes spanned a wide range, with 40%–
60% of probes detected in samples passing quality assessment (using
a 0.01 detection p-value threshold). In addition, there was no a priori
reason to expect an asymmetric distribution of changes [16]. Thus,
the 338 specimens passing the initial quality assessment were
normalized together via quantile normalization [31]. Post-
normalization residual MVA plots demonstrated that average
nonlinear bias was successfully removed. However, plots of PCA
results demonstrated that a SAM effect remained. Contrast
Table 1. Samples used for differential expression and principal component analysis.
Category Samples
Samples Plus
replicates
Excluded Samples
following QC
# of Samples Normalized and
eligible for DE (M/F)
# of Samples used
PCA/Cluster M/F
normal colon 55 55 3 52 (24/28) 52 (24/28)
adenoma 41 41 0 41 (28/13) 41 (28/13)
pMMR1, Stage A 3 3 0 3 (2/1) 3 (2/1)
pMMR1, Stage B 75 79 3 76 (42/34) 72 (42/30)
pMMR1, Stage C 47 52 5 47 (22/25) 43 (21/22)
pMMR1, Stage D 33 35 5 30 (18/12) 30 (18/12)
pMMR2, young 11 14 1 13 (11/2) 10 (8/2)
dMMR1, Sporadic 57 63 4 59 (27/32) 53 (21/32)
dMMR2, Inherited 11 14 0 14 (8/6) 11 (5/6)
dMMR3, Other 3 3 0 3 (3/0) 0
Total 336 359 21 338 (185/153) 315 (169/146)
QC, Quality Control.
DE, Differential Expression.
PCA, Principal Component Analysis.
M, male; F, female.
doi:10.1371/journal.pone.0020465.t001
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SAM effect for the majority of probes, a handful showed changes up
to 2-foldbetween SAMs that wereconsistent acrossall specimens on
each SAM and were not driven by outlier points. That is, consistent
SAM-by-probe interactions were observed. Thus, residuals from
linear models with SAM in the model fit on a per-probe basis to
quantile normalized data were used as the final normalized, SAM-
adjusted data. These linear models gave results within decimal dust
of empirical Bayes methods since the sample size is large [33].
Residual MVA plots, box plots and per-probe dot plots showed
no trend over time for the one sample serving as a cutting control
with tissue cut seven times over the two months it required to
process all of the tissue samples. Residual and pair-wise MVA plots
showed good overall agreement between technical replicates
placed on different SAMs. The largest SAM effect observed was
2.33-fold (log2 scale difference of 1.22), and only a handful of
probes had SAM effects of 2-fold. 91.5% (691/755) of probes had
SAM effect estimates ,1.2-fold.
Per-probe detection rates together with plots of per-probe
standard deviation (SD) over all normalized specimens (n=338)
versus average expression over all normalized specimens demon-
strated clear floor and ceiling effects in the abundance distribution.
A per-probe threshold SD of #0.4 in these specimens on the log2
scale was used to filter out ‘‘non-informative’’ probes in a manner
agnostic to group [34]. This resulted in 123 probes with 0%
detection rates, 37 saturated probes, and 376 mid-abundance
probes with low SD being filtered out, leaving 199 informative
probes with a SD .0.4.
Differential expression. Per-probe linear mixed effects
models with contrast statements were used to assess differential
expression using the quantile normalized, SAM-adjusted data.
Subject was included as a random effect in order to account for
correlation between multiple observations per subject (technical
replicates and the paired nature of all but one normal sample). A
SAM effect was included in the model to account for the degrees
of freedom used in the per-probe removal of the SAM effect.
Distributions of p-values and false discovery rates [35,36]
(calculated based on model results for all 735 miRNA probes)
were used to give a general sense of whether true differences exist.
Actual significance was assessed using the more conservative
Bonferroni corrected p-values based on 0.05/735=6.8610
25 for
each comparison together with fold-change cutoffs to incorporate
biological significance. Six main groups were compared: normal,
polyp, pMMR1 (old onset), pMMR2 (young onset), dMMR1
(sporadic) and dMMR2 (germline). Additional comparisons
included pMMR1 Stages B, C and D (Stage A with n=3 was
left out of this comparison due to the small sample size), as well as
the pMMR1 MSS and MSI-L groups.
Adjusting variables were included where appropriate to avoid
possible confounding with histology. Tumor stage was included as
a covariate in models assessing differences between tumor types to
adjust for possible imbalances of disease severity due to stage.
Location in the colon was not included as a covariate in models
comparing pMMR and dMMR tumors as this was considered to
be part of the biology of the tumors. No covariates were included
in models comparing the polyp or normal groups with other
groups since neither stage nor location in the colon are relevant for
these groups.
Visualization of Data. Visualization for the presence of
global effects was accomplished through unsupervised clustering
and PCA utilizing unique tissue samples only (318 of 338 samples);
the technical replicates were excluded from these analyses. For
samples with multiple technical replicates, the replicate specimen
labeled ‘‘1’’ was chosen. PCA analyses were conducted on
per-probe mean-centered and SD-scaled data using Partek [37]
and the R function prcomp [38]. Unsupervised clustering analyses
were performed on per-probe median-centered data in Partek
using Pearson’s dissimilarity matrix for calculation of distances
between individual samples and the average linkage method for
calculation of distances between two clusters. Points or specimen
labels were colored on plots by known clinical grouping
information.
Results
Sample characteristics
Following extensive quality assessment of the miRNA profiling
results (see Methods), 338 tissue samples from 268 patients were
utilized for further analysis. Normal and tumor tissue samples (not
including any of the technical replicates) included 52 normal
colonic mucosa, 41 tubulovillous adenomas, 158 adenocarcinomas
with pMMR selected for stage (3 Stage A, 72 Stage B, 43 Stage C
and 30 Stage D) and age of onset (148$50 years versus 10,50
years), and 64 adenocarcinomas with dMMR selected for both
sporadic (53 dMMR1) and inherited CC (11 dMMR2) as outlined
in Table 1.
All cases with sporadic dMMR (dMMR1) had MLH1
inactivation due to promoter hypermethylation. The inherited
dMMR group (dMMR2) was composed of cases having: (i) a
known germline mutation in either MLH1 (n=1) or MSH2 (n=3);
or (ii) loss of protein expression for MSH2 (n=3), MSH6 (n=2) or
PMS2 (n=2) by IHC and presumed to have a germline mutation
in these genes. Several cases with dMMR were not easily
categorized (dMMR3) and because of the small number, these
were eliminated from further analysis. Of the 268 subjects, 119
were female and 149 were male.
Global miRNA expression differences between normal
colon, adenoma and carcinoma
PCA and hierarchical cluster analyses, both unsupervised, were
used to visualize miRNA expression patterns present at a global
level in our expression dataset. Overall, there was a clear separation
between groups composed of normal, adenoma, pMMR1 and
dMMR1 derived tissues when examined by both unsupervised PCA
(Figure 1A) and hierarchical clustering (Figure 1B) using the set
of 199 ‘‘informative’’ probes obtained as described in Methods. Of
interest, however, hierarchical clustering also suggests the presence
of two sub-populations for the dMMR1 group of tumors, which
appears to be driven by a cluster of miRNAs (the majority from
chromosome 14) showing low expression in one group and high
expression in the other (indicated by arrow in Figure 1B).
The global miRNA expression patterns were then visually
examined in various pre-defined tumor sub-groups to determine if
these could be distinguished. The PCA plots for these analyses are
shown in Figure 2 (data not shown for the hierarchical cluster
analyses). Within the pMMR1 group of tumors, there were no
apparent discernible differences based on stage, either across all
three stages or between any two stages (Stage A not included due
to small numbers), or based on gender. Additionally, no separation
of groups was visible between tumors with an older age of onset
($50 y/o, pMMR1) and those with a younger age of onset
(,50 y/o, pMMR2). An analysis of tumors within each of the two
dMMR subtypes, dMMR1 (somatic) versus dMMR2 (germline),
also showed no discernible differences.
Because tumors are often classified by their MSI status (MSS,
MSI-L and MSI-H), these three groups were further examined
for expression differences together, then systematically in pairs.
As expected, the MSI-H group (defined as dMMR) clustered
miRNA Expression in Colon Polyps and Cancer
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pMMR). However, the MSI-L and MSS groups showed no
discernible differences (Figure 2).
Differential expression between normal colon, adenoma
and carcinoma
We conducted group-based statistical comparisons on a probe-
by-probe basis using linear models for several pre-defined analyses
in an effort to identify statistically significant differentially
expressed miRNAs. Overall, highly significant differences were
observed between several of the groups for specific miRNAs
using a Bonferroni corrected p-value threshold for signifi-
cance (6.8610
25). Table 2 provides a count of the miRNAs
demonstrating significant expression fold changes at varying
cutoffs ($2.0 and $4.0). Table 3 shows the nine statistically
significant differentially expressed miRNAs with the greatest fold
change (fold change of $4), while Figure S1 shows the dot plots
for each of these among the various tissue subgroups.
The change in expression level that occurs in the normal to
adenoma to carcinoma sequence for each of the nine miRNAs can
clearly be seen in Figure S1. Five of the nine show consistent
changes across all groups compared to normal, with miR-135b
and miR-31 up-regulated and miR-1, miR-137 and miR-9 down-
regulated in all samples. HS_29 is up-regulated in all of the
carcinomas but not in the polyps, miR-552 and miR592 are up-
regulated in the polyps and pMMR tumors but not the dMMR
tumors, and finally, miR99a is down-regulated in polyps with
intermediate levels in both the pMMR and dMMR tumor groups.
Using the Bonferroni P-value threshold along with a fold change
in expression level of $2, a total of 54 miRNAs were identified
among the various comparisons (Table 2, Table S1). Thirty one
miRNA were differentially expressed between normal colon tissue
and adenomas. A comparison of normal colon tissue to the two
main carcinoma groups (pMMR1 and dMMR1) identified 31 and
28 significant miRNAs, respectively, utilizing these criteria.
Finally, 6 and 11 significant miRNAs were identified when
adenomas were compared to the two carcinoma groups. The heat
map, shown in Figure 3, illustrates the relative expression
differences of these miRNAs among the groups being studied.
Of interest, the majority (23 of the 31) of miRNAs that were
differentially expressed between normal and adenoma with fold
changes of $2 were also differentially expressed in the comparison
of normal to both the pMMR and dMMR tissue groups, for
example miR-135b and miR-31 (Table S1). Additionally, the
Figure 1. Plots of principal components from PCA analyses and unsupervised hierarchical clustering. (A) Plots of principal components
from PCA analyses. Horizontal axis corresponds to principal component 1 (PC1), vertical axis corresponds to PC2, depth axis corresponds to PC3. The
percent of variation explained by a particular PC is indicated in the axis label. Points are colored by group status with blue representing normal
epithelium, purple representing polyp, green representing pMMR1, and red representing dMMR1. Two different orientations are provided. (B)
Unsupervised hierarchical clustering of miRNA profiles using the set of 199 ‘‘informative’’ probes obtained as described in Methods. Samples are
indicated along the horizontal axis and include normal colon, adenomas, pMMR1 carcinomas and dMMR1 carcinomas with group membership
indicated by the color bar between the dendogram and the heat map. miRNAs are indicated by the vertical axis. The color bar below indicates level of
expression.
doi:10.1371/journal.pone.0020465.g001
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these were consistent between adenoma and carcinoma. In
addition to the similarities noted for the adenoma and carcinoma
groups, however, differences in expression were also identified. Of
the 43 miRNAs that were significantly differentially expressed with
fold changes of $2 in the two tumor groups, 20 did not meet these
criteria in the polyp group (e.g., miR-375, mir-147, etc.), although
several others miRNAs had significant but smaller levels of
expression difference in the polyp group (e.g., miR-188-5p, miR-
210) (Table S1). When the tumor groups were compared directly
to the polyp group, 20 miRNAs were identified; 9 up-regulated
(e.g., miR-483-3p, miR34b) and 11 down-regulated (e.g., miR-
552,miR-592).
Although PCA and cluster analysis was able to separate the
pMMR1 and dMMR1 subgroups (Figure 1), there were surprisingly
few miRNAs that were significantly differentially expressed between
these two groups (Table 2 and Table S1).O n l yf o u rm i R N A s
(miR-31, miR-224, miR-552, miR-592,) were found at a 2-fold
change or higher. As noted for the adenoma comparisons, the
majority of miRNAs that were differentially expressed between the
normal colon tissue and the pMMR1 group with fold changes $2
were also differentially expressed in the comparison of normal colon
tissue to the dMMR1 tissue group. Again, the levels and direction of
these changes relative to normal for most of these miRNAs were
consistent between these two comparisons (Table S1).
A number of additional pre-planned comparisons showed
minimal differences between specific subgroups. Two of these
comparisons included pMMR1 versus pMMR2 (old vs. young) and
dMMR1 versus dMMR2 (sporadic vs. germline) (Table 2 and
Table S1). Of note, differences between these groups were also not
evident in the PCA and cluster analyses. Other analyses that did not
demonstrate any significant expression difference between the
groups with large fold change ($2-fold change) included: 1) MSS
versus MSI-L; 2) stage within the pMMR1 group; 3) proximal
versus distal normal epithelium; and 4) normal epithelium from
patients with dMMR tumors versus those from patients with
pMMR tumors (data not shown). For proximal versus distal origin
of the polyps, 1 miRNA of significance was identified meeting this
threshold (miR-31 with a fold change of 3.25).
miRNA cluster on Chromosome 14
For those miRNAs that were significantly differentially
expressed (p=6.8610
25 cut-off) at a fold change of 1.41 or
higher (log2$0.5) in either direction, their chromosomal distribu-
Figure 2. Plots of principal components from PCA analyses. Horizontal axis corresponds to principal component 1 (PC1), vertical axis
corresponds to PC2, and depth axis corresponds to PC3. Points are colored by group status. The percent of variation explained by a particular PC is
indicated in the axis label. (A) pMMR1 evaluated by Dukes stage; (B) evaluation by age of onset (pMMR1 - old and pMMR2 - young). (C) evaluation of 2
groupings of dMMR cases (dMMR1 - epigenetic silenced MLH1 and dMMR2 - germline); (D) the pMMR1 groups MSI-L and MSS tumors. Colors for each
of the groups being compared are shown in the upper right legend box.
doi:10.1371/journal.pone.0020465.g002
miRNA Expression in Colon Polyps and Cancer
PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20465tion was examined to determine if there was either over- or under-
representation on a particular chromosome compared to what
might have been expected when compared to the overall
frequency distribution of all miRNAs tested. When the distribution
of significantly differentially expressed miRNAs from all compar-
isons was considered over chromosomal locations (using the same
p-value threshold and fold change), over twice as many were found
on chromosome 14 than expected (Figure 4). When this
distribution was considered separately for each comparison
(Table 2), the chromosome 14 over-representation was due
almost entirely to the normal colon tissue – adenoma comparison.
Hierarchical cluster analysis of the probes was performed using the
95 significant miRNAs identified with a fold change $1.41 for the
normal colon tissue - adenoma comparison in order to assess
which miRNAs were behaving similarly. One of the clusters
resulting from this analysis contained 16 miRNAs, all of which
mapped to a single location at chromosome 14q32. The probes in
this cluster showed decreased expression in adenomas with
intermediate levels in both the pMMR and dMMR carcinoma
groups. Examples for two of these miRNAs, miR-379 and miR-
411 are shown in Figure 5.
Discussion
We examined the miRNA expression pattern in a large set of
clinically and molecularly well-characterized tissue samples. Several
key observations were made. First, unsupervised PCA and cluster
analysis demonstrated that normalcolon tissue, adenomatoustissue,
pMMR1-derived carcinomas and dMMR1-derived carcinomas
were all clearly separated, supporting the presence of unique
molecular differences between these groups of tissue. Although
distinctions between normal/tumor and pMMR/dMMR tumors
have been previously reported [13,14,16,17,18,19,20], this is the
first report in which a set of well-defined tubulovillous adenomas
have been tested for global expression differences and shown to be
distinct from normal colon and both pMMR- and dMMR-derived
tumor tissue. The few reports on miRNAs in colon adenomas have
Table 2. Number of miRNAs meeting the specified
significance criteria of p,6.8610
25 and with various levels of
Fold Change (up or down) for specified comparisons.
Comparison Fold Change $2.0 Fold Change $4.0
normal vs. adenoma 31 6
normal vs. pMMR1 31 3
normal vs. pMMR2 25 (all) 3 (all)
normal vs. dMMR1 28 5
normal vs. dMMR2 28 (21) 5 (4)
Adenoma vs. pMMR1 6-
Adenoma vs. pMMR2 7( 5 ) -
Adenoma vs. dMMR1 11 2
Adenoma vs. dMMR2 11 (5) 1 (1)
pMMR1 vs. dMMR1 41
pMMR1 vs. pMMR2 --
dMMR1 vs. dMMR2 --
Total unique 54 9
Numbers in parentheses indicate the number of miRNAs in common with the
row directly above.
doi:10.1371/journal.pone.0020465.t002
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20465largely been restricted to the analysis of only selected targets
[21,22,23,24,25].
Second, probe-by-probe comparisons in various group com-
parison analyses identified a set of changes in miRNA levels that
are consistent with a normal to adenoma and adenoma to
carcinoma sequence. A comparison of normal tissue to adenomas,
normal tissue to pMMR carcinomas and normal tissue to
dMMR carcinomas identified 31, 31 and 28 miRNAs that were
Figure 3. Unsupervised hierarchical clustering of miRNA profiles using the set of 54 probes meeting the Bonferonni significance
criteria (p-value ,6.8610
25) and $2-fold change in either direction by differential expression analyses. Samples are indicated along
the horizontal axis and include normal colon, adenomas, pMMR carcinomas (1 and 2 combined) and dMMR carcinomas (1 and 2 combined) with
group membership indicated by the color bar between the dendogram and the heat map. miRNAs are indicated by the vertical axis. The color bar
below indicates level of expression.
doi:10.1371/journal.pone.0020465.g003
Figure 4. Distribution of miRNAs across the chromosomes. Open bars represent the total number of probes available on the Illumina platform
distributed by known chromosomal location. Shaded bars represent those miRNAs with significant fold changes according to Bonferroni criteria that
are greater than 1.41 in either direction (i.e., log2$|0.5|).
doi:10.1371/journal.pone.0020465.g004
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20465differentially expressed with a 2-fold change or higher, respective-
ly. Of interest, the majority of miRNAs that were differentially
expressed between normal and adenoma were also differentially
expressed in both the pMMR and dMMR tissue groups. The
miRNAs showing the greatest difference in expression between
normal and adenoma that were also similarly changed in the
tumor groups include miR-135b (6.89-fold), miR-31 (4.76-fold),
miR-137 (-10-fold), miR-1 (-4.64-fold), miR-9 (-4.43-fold). Fur-
thermore, of the 31 miRNAs differentially expressed between
normal tissue and adenoma ($2-fold change and p-value #6.8e-
5), 11 up- and 20 down-regulated, 26 (84%) were also differentially
expressed with a fold change of $1.41 in the normal/pMMR1
comparison while this was the case for 27 (87%) in the normal/
dMMR1 comparison (Table S1). Importantly, all but one of
these miRNAs was differentially expressed in the same direction,
the single exception being miR-552 for the normal/dMMR1
comparison. Thus, the primary difference observed between the
adenoma and carcinoma comparisons for many of the miRNAs
appears to be a difference in the magnitude of the fold change
(Table S1). In addition to these similarities, however, significant
differences were noted. Several of the miRNAs identified were
differentially expressed in the normal-carcinoma comparisons but
not statistically different in the normal-adenoma comparison, for
example miR-375, miR-196b, miR-153, miR-147 and miR-642
(Table S1). Note that the fold difference in miRNA expression as
measured by the Illumina array is relative and not absolute.
Determination of the absolute miRNA expression differences
would require the use of more quantitative methods. As we have
previously described the accuracy of this platform [16,39],
additional studies to confirm miRNA expression differences were
not performed for this report.
These data fit well with a multi-hit model of tumorigenesis. In
this model, some initiating events are required to transition from
normal to adenoma, while additional events are required to
transition from adenoma to carcinoma. The substantial overlap for
those miRNAs that are both statistically significant and show large
fold changes between the normal-adenoma and the normal-
carcinoma comparison suggests that many, if not most, of these
miRNA changes are acquired early and persist throughout the
later stages of malignant transformation. It is important to note,
however, that these data should be interpreted with caution. The
measured differences in these experiments reflect the average
change observed for all cells present in the tissue of interest. Given
the presence of substantial cellular heterogeneity, specific cell-
based studies (such as in situ hybridization) will be required to
distinguish those changes originating from the neoplastic cells
compared to those from stromal or inflammatory cells. Thus, some
of the early and persistent changes detected in these analyses may
be due to changes in non-tumor related cellular processes.
Additionally, the magnitude of expression differences is also
dependent on the extent of the cellular heterogeneity, that is, the
ratio of neoplastic to non-neoplastic cells.
Of the nine miRNA targets that demonstrated the largest fold
changes, six were found in the normal to adenoma comparison
(Table 3). Five of these showed similar expression differences in
the two carcinoma groups. Of these six, four have not previously
been implicated in adenoma formation (miR-31, miR-1, miR-9
and miR-99a) and, thus, represent novel findings. Of interest,
miR-9 has been implicated in the c-myc pathway [40], an
oncogenic pathway well characterized in CC. A great deal of
literature exists for miR-31, demonstrating that this miRNA
regulates a number of essential signaling pathways in mammalian
cells and has been implicated in several aspects of tumorigenesis,
including metastatic progression and tumor cell growth [41]. miR-
1 is abundantly expressed in normal skeletal muscle and is
implicated in muscle differentiation [42]. In tumor conditions,
miR-1 was found to be down-regulated leading to the deregulation
of genes associated with myogenesis [43].
Two of the miRNAs demonstrating the largest fold changes for
the normal to adenoma comparison, miR-137 (decreased
expression) and miR-135b (increased expression), have previously
been reported to be important early events in colon carcinogen-
esis. For miR-137, Balaguer et al. [21] demonstrated the specific
involvement of this miRNA in both colon adenomas and
carcinomas. They demonstrated that the decreased expression is
due to abnormal hypermethylation and that transfection of this
miRNA in CC cell lines significantly inhibited cell proliferation.
This study, along with others in oral cancer and in glioblastoma
[44,45], strongly implicates a tumor suppressor model for miR-
137. In another study, Nagel et al. [24] found that miR-135a and
135b were up-regulated in both colon adenomas and carcinomas,
consistent with results from our study. In addition, they showed
Figure 5. Dot plots demonstrating expression distribution within study groups. Vertical axis is expression on the log2 scale. Horizontal axis
indicates group membership and sample sizes per group. Dashes indicate mean expression in that group. miRNA names are indicated in headers.
doi:10.1371/journal.pone.0020465.g005
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PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e20465that miR-135 targets the 39 untranslated region of APC, suppresses
its expression, and induces downstream Wnt signaling. The APC
gene has long been recognized as a key tumor suppressor in
sporadic and hereditary CC [46]. In addition to the adenomas, it
is important to note that miR-137, miR-135 and the novel
miRNAs miR-31, miR-1, miR-9 were all found to be significantly
differentially expressed in both pMMR and dMMR tumors,
suggesting that these alterations are biologically involved in these
two very different types of tumors. Of interest, we have recently
shown that miR-183, one of the miRNAs that is highly expressed
in both colon adenomas and carcinomas, negatively regulated
EGR1 expression, which in turn affects the expression of PTEN.
Further, miR-183 is implicated in tumor cell migration by the
negative regulation of both EGR1 and PTEN [47].
Chr 14q32 contains one of the most miRNA rich regions in the
human genome with over 25 miRNAs organized into at least five
clusters [48]. Results from our current study demonstrated
significant involvement of this miRNA cluster in CC development,
with decreased expression in adenomas and intermediate levels
(between normal and adenoma) in the carcinoma subgroups
(Figure 3). The corresponding orthologous miRNAs in mice are
maternally imprinted and are controlled by imprinting control
regions present upstream of these miRNA clusters [49]. Previous
reports have shown that miR-127 present in this region is
epigenetically regulated and can be modulated by chromatin-
modifying drugs [50]. Further, 14q32 miRNAs are also down-
regulated in several solid tumors [51] including osteosarcoma [52].
In a recent study comparing mice iPS cells with embryonic stem
cells, the complete miRNA locus was down regulated due to
hypermethylation in the imprinting control regions [53]. Based
on these previous studies, it is very likely that the transition
from normal colon to adenoma is characterized by epigenetic
alterations that lead to the down-regulation of the 14q32 miRNAs
in colon adenomas.
As previously published [13,16,17,18,19], our studies also
demonstrate that tumors with defective DNA mismatch repair
differ with respect to their miRNA expression profile from those
with proficient DNA mismatch repair. Although these two tumor
groups were separated by both PCA and cluster analysis, only a
few miRNAs demonstrated statistically significant expression
differences ($2-fold) between the two (miR-31, miR-552, miR-
592, miR-224). It is important to note, however, that many of the
significant miRNAs identified among the three main two-group
comparisons between normal-adenoma, normal-pMMR and
normal-dMMR (Table S1) were common to each other.
Collectively, these observations indicate that although the
clinically relevant pMMR and dMMR tumor subtypes differ with
respect to their global miRNA expression patterns, the specific
changes observed for these two tumor types are also quite similar
to each other. As noted above, this similarity may reflect critical
common tumor-specific processes, or they may also reflect local
non-tumor-related cellular functions.
There are several noteworthy negative findings in this study.
Among the pMMR1 group of tumors, for example, no separation
of groups was observed by unsupervised PCA and cluster analysis
for stage, gender, age of onset or between the MSS and MSI-L
groups. These observations are consistent with the differential
expression analyses in which there were few or no statistically
significant differences between the comparisons. An analysis
across tumors for each of the two dMMR subtypes (dMMR1 and
dMMR2) also showed no discernible differences. All dMMR
tumors, regardless of their origin (germline or epigenetic), dem-
onstrated similar global miRNA expression patterns. This is the
first systematic comparison of these two different subgroups of
MMR tumors. Overall, these data suggested that the underlying
molecular characteristics among those cases within both the
pMMR group (young, old, Stages I-IV, MSS, MSI-L) and within
the dMMR group (different MMR genes, different mechanisms
of gene inactivation) are more similar to each other than
expected. Although there may be a greater degree of heteroge-
neity at the level of gene mutations and among genes involved in
particular pathways, the overall miRNA profiles appear to be
fairly homogeneous. Alternatively, more subtle expression
differences that have significant biologic effects may still be
present but not easily distinguishable with the methods used in
this study. Of note, however, the cluster analysis did suggest
the possible presence of two sub-populations within the dMMR1
group of tumors, even though these were restricted to cases
having epigenetic inactivation of MLH1 (Figure 1B).A d d i -
tional studies will be required to confirm this latter intriguing
observation.
Tumors with pMMR are characterized by the presence of
widespread chromosomal gains and loss, and these changes have
been detected by a variety of techniques such as Allelic Imbalance
and array CGH studies [54]. Tumors with dMMR on the other
hand, demonstrate few of these changes and overall tend to be
near-diploid [2]. The nine most significant differentially expressed
miRNAs identified in this study (Table 3) all map to regions
commonly found to have gains or losses in CC (loss of 1p, 2p,
5q, 9p, 15q, 18q and 21q and gain of 1q, 7q and 20q) [54].
Chromosomal alterations as measured by array CGH [55] for a
subset of the cases could not explain the expression differences
observed for any of the six miRNAs examined (data not shown),
although the data for those miRNAs that map to multiple sites
(mir-9, 1q, 5q, 15q; and miR-1, 18q and 20q) are more difficult to
interpret. Overall, these data suggest that copy number differences
are not likely to be responsible for the expression differences
observed for the six miRNAs examined. For at least one of these,
mir-137, methylation appears to be the primary mechanism
leading to abnormal expression [21].
In summary, this is the first systematic analysis of global miRNA
changes in colon adenomas along with several well-defined sub-
groups of colon adenocarcinomas. The data presented provides an
expanded view of miRNA changes that occur in the process of
carcinogenesis. We have identified several miRNAs (miR-31, miR-
1, miR-9, miR-99a, miR-137 and miR-135b) that show significant
differential expression in adenomas compared to normal colon
tissue, with several of these linked to critical pathways previously
identified for CC, including APC/WNT signaling and cMYC. The
finding of several novel miRNAs provide the opportunity to
identify associations with known CC pathways or the identification
of novel pathways and mechanisms that might be important in the
transition from normal to adenoma and from adenoma to
carcinoma. We also provide evidence that the miRNA changes
detected in the early stages of disease are important in both
pMMR and dMMR tumors. This data suggested the involvement
of common biologic pathways in both types of tumors, in spite of
the presence of numerous molecular differences between them,
including differences at the miRNA level. Finally, we also
demonstrate a high degree of similarity between a number of
tumor subgroups, again highlighting the involvement of common
biologic pathways.
Supporting Information
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